Chinese Scientist Unite Together to Tackle With COVID-19
Chinese Scientist Unite Together to Tackle With COVID-19
PR82933
BEIJING, Feb. 19, 2020 /PRNewswire=KYODO JBN/
Reported by Science & Technology Daily:
As to the battle against the COVID-19, Chinese Ministry of Science and Technology
(MOST) has been launched the program of "Dealing With the Outbreak of COVID-19
Using Science and Technology", a program including four batches of 20 emergency
projects until now. Moreover, MOST re-examining two major scientific and technological
projects, including the "Creation of Important Innovative New Drugs" and the "Prevention
and Treatment of Severe Contagions", and a series of national essential research and
development plans. Recently, some important achievements from these projects have
already been implemented in the front line of epidemic prevention and control.
When it comes to drug screening, front-line staff from different research teams
collaborated on the basis of existing researches, making great efforts to
systematically and massively screen the drugs that have been on the market
already or already go into clinical trials. As a consequence, they discovered
potentially effective anti- coronavirus drugs, such as Chloroquine Phosphate,
Remdesivir, and Favipiravir. Furthermore, in recent days, researchers have
urgently launched some clinical trials and the results show that the curative
effect of drugs on patients is increasingly obvious.
Based on the R&D level and preliminary accumulation in the field of cell therapy,
traditional Chinese medicine and plasma therapy in China, the clinical trials of
the three therapies organized by the "Joint Prevention and Control Group" have been
gradually carried out, and they are playing significant role in curing critically ill patients.
For the purpose of providing more cutting-edge and effective solutions to the epidemic using
stem cell therapy, the leaders of the MOST went to the Innovation Institute of Stem Cell
and Regenerative Medicine of the Chinese Academy of Science to confirm their progressing.
A new cellular drug called CAStem supposed to cure COVID-19 was created, and it has already
made major progress in the experiment about the treatment of the severe acute respiratory
distress syndrome (ARDS) previously. The research team has applied for emergency approval
from China National Medical Products Administration, and it is cooperating with relevant
medical institutions. So far, the CAStem has already been approved by the Ethics Committee,
and is ongoing clinical observation and evaluation.
An emergency project titled "Clinical Study on the Prevention and Treatment of COVID-19
by Integrated Chinese and Western Medicine" was officially launched on February 3 with
the support from the MOST. "The positive curative effect has been shown in treating COVID-19,"
said Zhang Boli, the project leader and the headmaster of Tianjin University of Traditional
Chinese Medicine. It was reported that a total of 23 patients had been cured and discharged
from Hubei Provincial Hospital of Integrated Traditional and Western Medicine and Wuhan
Hospital of Traditional Chinese Medicine.
With regard to the field of plasma therapy, China National Biotech Group has
completed the collection of plasma from some convalescent patients, as well as
the preparation of special immune plasma products and special immune globulin
of novel coronavirus on February 13. Through strict blood biosafety testing,
virus inactivation, and antiviral activity testing, etc., special immune plasma
has been successfully prepared for clinical treatment and has already been put
into clinical treatment of severely ill patients.
In terms of field of vaccine research and development, the Chinese Center for
Disease Control and Prevention (CDC) had successfully isolated the first
COVID-19 virus strain on January 24, which was recognized by the World Health
Organization and other international agencies. Several new type of vaccines for
COVID-19 have started the animal testing phase, which bring hope to all.
SOURCE: Science and Technology Daily
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。